Can a new infusion drug tame advanced solid tumors?

NCT ID NCT06087770

First seen Jul 23, 2026 · Last updated Jul 24, 2026 · Updated 1 time

Summary

This early-phase trial is testing an experimental drug called SM3321 in people with advanced solid tumors that have stopped responding to standard treatments. The main goal is to see if the drug is safe and tolerable, and to find the best dose. Participants receive SM3321 as a weekly intravenous infusion over 28-day cycles.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
an experimental drug called SM3321 given by intravenous infusion once a week
What this could lead to
If safe and effective, SM3321 could offer a new treatment option for people with advanced solid tumors who have run out of standard therapies.
What could go wrong
This is an early, small phase 1 trial focused on safety, not yet on how well the drug works. The drug may cause side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED OR METASTATIC SOLID TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm Neoplasm Metastasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Shanghai General Hospital

    Shanghai, Shanghai Municipality, 201210, China

  • Sun Yat-sen Memorial Hospital, Sun Yat-sen University

    Guangzhou, Guangdong, 510120, China

  • The second affiliated hospital Zhejiang university School of Medicine

    Hangzhou, Zhejiang, 310009, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.